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Lung transplantation in cystic fibrosis may improve survival fo r 
patients w ith  low 5-year predicted survival. Identifying characteris­
tics tha t affect post-transplantation survival may improve patient 
selection and survival benefit. Using Cystic Fibrosis Foundation Pa­
tien t Registry and United Network fo r Organ Sharing data, we 
identified 845 lung transplant recipients from  1991-2001, and 
12,826 control patients from  1997. We used Cox proportional haz­
ards models to identify variables tha t influence post-transplantation 
survival. To estimate the survival benefit of transplantation fo r pa­
tients affected by identified variables, we compared Kaplan-Meier 
survival curves of transplanted and control patients stratified by 
5-year predicted survival. Post-transplantation survival improved 
annually. Youth, Burkholderia cepacia, and cystic fibrosis-related ar­
thropathy increased the post-transplantation hazard of death. 
Compared w ith  control subjects, transplanted adults w ith  a 5-year 
predicted survival of less than 50% w ithou t B. cepacia or arthropathy 
have improved survival. Transplanted adults w ith  B. cepacia, ar­
thropathy, or a 5-year predicted survival of greater than 50% have 
decreased survival. Transplantation never improves survivorship fo r 
pediatric patients. Patients w ith  arthropathy, B. cepacia infection, or 
younger age derive no aggregate survival benefit and must appraise 
carefully the high risk of decreased post-transplantation survival. 
Adult patients w ith  low 5-year predicted survival w ithou t B. cepacia 
infection should receive priority  fo r lung transplantation.
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Cystic fibrosis (CF) is the most common genetically determined 
disease in the United States. It causes multisystem disease pri­
marily involving the gastrointestinal tract and the respiratory 
system. Approximately 80% of patients die of progressive respi­
ratory disease (1). Lung transplantation, as heart-lung, cadaveric 
bilateral single lung, and living-donor procedures, remains the 
most aggressive treatment of end-stage lung disease since its 
introduction (2-4). However, complications of lung transplanta­
tion are the second most frequent cause of death for patients 
afflicted with CF, accounting for approximately 12% of deaths 
in 2002 (1).
Because of the high risks associated with lung transplantation, 
we recently analyzed its effect on survival in patients with CF 
stratified by 5-year predicted survival. We used the logistic re­
gression survival model of CF that we previously validated to 
determine 5-year predicted survival (5). This model includes 
nine variables and one interaction to make accurate predictions
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of 5-year survival: age, sex, FEVi, weight-for-age z score, pancre­
atic sufficiency status, diabetes status, Staphylococcus aureus 
infection status, Burkholderia cepacia infection status, and num­
ber of acute exacerbations of CF in 1 year, and an interaction 
term between B. cepacia and number of acute exacerbations.
Using this model, we demonstrated that only patients with a 
less than 30% chance of living 5 years had a clear survival benefit 
from lung transplantation (6). Lung transplantation decreased 
survival for patients with a 5-year predicted survival greater than 
50%. Patients with a 30 to 50% chance of 5-year survival had 
essentially no survival effect of lung transplantation in 5 years 
of follow-up. Physicians wishing to apply this model to individual 
patients can use worksheets that we have provided to manually 
calculate a 5-year predicted survival (aje.oupjournals.org/cgi/ 
content/full/153/4/345/DCl) (or contact the authors).
In our earlier analysis, patients stratified before transplanta­
tion into different 5-year predicted survivorship groups all had 
the same post-transplant survivorship (6, 7). However, if differ­
ent factors determine pre- and post-transplant survivorship, pa­
tients with similar predicted 5-year nontransplanted survival may 
have significant differences in post-transplantation survival. 
Identification of specific pretransplantation variables that predict 
post-transplantation survivorship may improve patient selection 
for the procedure.
Patients infected with B. cepacia have poor post-transplantation 
survivorship compared with other transplanted patients (8, 9). Nine 
different B. cepacia genomovars appear to alter survivorship to 
different degrees (10, 11). However, because B. cepacia markedly 
reduces nontransplanted survival, there may still be a survival bene­
fit from transplantation despite the reduced post-transplantation 
survival. There have been no comparisons of survival between 
transplanted and nontransplanted patients with B. cepacia stratified 
by expected survival.
Other than B. cepacia, no pretransplantation variables have 
been shown to affect post-transplantation survival (12, 13). We 
used the U.S. CF Foundation Patient Registry (CFFPR) and 
the United Network for Organ Sharing (UNOS) database to 
analyze post-transplantation survivorship to discover additional 
variables that may help predict success or failure with lung trans­
plantation for patients with end-stage lung disease from CF. The 
CFFPR contains data for 33,415 unique patients with CF followed 
at 117 certified CF care centers across the United States (1). An 
estimated 90% of all patients with CF in the United States are 
included in the CFFPR (1). Some of the results of this study 
have been previously reported in abstract form at the North 
American CF Conference, 2004, in St. Louis, MO (14).
METHODS
We used the 1988-2001 CFFPR and the 1988-2002 UNOS data set to 
identify patients for study. The CF Foundation, UNOS, and the Univer­
sity of Utah Investigational Review Board each reviewed and approved 
our project. Written consent was waived.
Patients in the transplantation group were matched between the 
CFFPR and the UNOS data set using exact birth date, sex, and year of 
transplantation to ascertain exact transplantation dates. We calculated
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survival from the day of transplantation to December 31,2001, including 
death or loss to follow-up. Patients were considered lost to follow-up 
from January 1 of the year after the last recorded data for that patient 
in the CFFPR.
Patients included as controls had not received solid organ trans­
plantation before 1997. To compare transplant survival with the latest 
available 5-year period for control subjects, survival was calculated 
from January 1,1997, to December 31,2001, death, lung transplantation, 
or loss to follow-up. Survival was censored on transplantation.
We used our logistic regression model of 5 -year survivorship to predict 
survival for each control and transplant recipient (5). Data required for 
the calculation included birth date, sex, weight-for-age z score, FEVj 
normalized to percent predicted (FEVi%), diabetes status, S. aureus and
B. cepacia status, and number of acute exacerbations in 1997 for control 
subjects or in the year before transplantation for transplant recipients (5). 
We used Splus (Insightful Corp., Seattle, WA) (15) to calculate FEVjX 
and weight-for-age z score and to apply our logistic regression model to 
calculate 5-year predicted survival, as previously described (5, 16).
To detect variables that plausibly alter the hazard of post-transplanta­
tion death, we used variables from the CFFPR, excluding those pertaining 
to clinical investigations or with sparse data. Using forward and backward 
stepwise selection procedures, we developed a final candidate multivariate 
Cox proportional hazards model of death after lung transplantation for 
CF (17).
We created univariate Cox proportional hazards models using each 
variable. Variables with an absolute z statistic of less than 1 were 
rejected from further consideration. Remaining variables were candi­
dates for the forward model construction procedure. After creating a 
multivariate Cox proportional hazards model by the standard forward 
model construction procedure (17), we applied a backward selection 
procedure with a criterion of a p value of less than 0.05 to retain only 
variables that had a significant effect in the multivariate Cox model (17).
For the backward stepwise selection procedure, we included all 
variables with sufficient data and plausible biological effect on survival 
in a multivariate Cox model. We sequentially removed variables with 
a p value of greater than 0.05 to arrive at a final candidate multivariate 
Cox model. We examined remaining variables for two-way interactions, 
eliminating interactions involving small numbers of patients or interac­
tions with year of transplantation because there can be no impact on 
patient selection (17).
We evaluated the survival effect of variables included in the final 
multivariate Cox proportional hazards model. For each covariate in 
the Cox model, we selected a control group of patients and a transplant 
group of recipients. After selection, we stratified the patients by 5-year 
predicted survival of less than 50%, between 50 and 90%, and greater 
than 90%. Within strata, we used Cox proportional hazards models to 
test whether transplantation affected survival.
RESULTS
Patients
The 1991-2001 CFFPR contains 30,930 patients. From 1991 
through 2001,1,379 patients in the CFFPR underwent lung trans­
plantation. We excluded 209 patients who also underwent heart, 
liver, or other solid organ transplantation, 126 patients missing 
pulmonary function data, 38 missing microbiology data, and 2 miss­
ing weights. Of 1,004 patients for whom we were able to calculate 
a 5-year predicted survival, we ascertained a transplantation date 
for 845, the final number of patients included in this study.
The 1997 cohort of nontransplanted patients numbered 
20,650 patients. We excluded 5,604 patients missing pulmonary 
function information (3,338 were too young for testing, 2,266 
were simply missing), 268 patients of ethnic or racial back­
grounds for whom we lack equations to normalize FEV^o, 1,133 
patients missing acute exacerbations data, 799 patients missing 
microbiology data, 13 patients missing pancreatic sufficiency 
data, and 7 patients missing weight information. This left 12,826 
patients for whom we were able to calculate a 5-year predicted 
survival.
Model Development
We started with a total of 24 variables with plausible biological 
effects for analysis (Table 1). Other than variables included 
in the 5-year predicted survival model (5), no variables were 
significant predictors of survival by univariate logistic regression 
in the control group of patients. The 5-year predicted survival 
itself was not a predictor of post-transplantation survival using 
univariate logistic regression. Transplant recipients had lower 
weight and pulmonary function, and more diabetes, pancreatic 
insufficiency, infections, and acute exacerbations of disease (Ta­
ble 2). The incidence of each condition among the transplant 
recipients was sufficient to test the variables for effects on post­
transplantation survival.
Univariate Cox proportional hazards models identified 10 
variables as potentially significant predictors of survival with a p 
value of 0.2 or less: age (p = 0.0004), acute exacerbations (p = 
0.02), arthropathy (p = 0.01), B. cepacia (p = 0.0004), FEV^o 
(p = 0.2), liver disease (p = 0.15), mucoid Pseudomonas aerugi­
nosa (p = 0.065), nonmucoid P. aeruginosa (p = 0.18), weight- 
for-age z score (p = 0.16), and year of transplantation (p =
0.008).
Forward and backward selection procedures both identified 
a four-variable candidate model of the hazard of death after 
lung transplantation for CF, which includes year of transplanta­
tion, age at transplantation, infection with B. cepacia, and ar­
thropathy (Table 3). We additionally considered the effect of 
B. cepacia genomovar but found that there is insufficient infor­
mation in the CFFPR to analyze the effects after transplantation.
The interaction between age at transplantation and B. cepacia 
was significant and was included in the final Cox proportional 
hazards model (Table 3). The coefficient for age (-0.0252; Table 
3) shows that the hazard of death decreases with age. The signifi­
cant interaction with B. cepacia infection implies that the age 
effect on the hazard of death is altered by the status of B. cepacia 
infection. With B. cepacia infection, each additional year of age 
is associated with a 6% increase in the hazard of death. Of 
the nine variables and one interaction in our 5-year predicted 
survival model of nontransplanted patients with CF, only the
TABLE 1. VARIABLES TESTED FOR SURVIVAL EFFECT
Age,yr*
Acute exacerbations, no./yr*
Alcaligenes (Achromobacter) xylosoxidans 









Liver disease, three variables*
Methicillin-resistant Staphylococcus aureus 
Mucoid Pseudomonas aeruginosa*
Nonmucoid Pseudomonas aeruginosa*






* Univariate Cox proportional hazards models found 10 variables were potentially 
significant predictors of survival (p <  0.2; see Results). Stepwise selection proce­
dures eliminate all but age, arthropathy, B. cepacia, and year of transplantation 
from the multivariate Cox proportional hazards model.
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TABLE 2. PATIENT CHARACTERISTICS AND THE EFFECT OF STRATIFICATION BY 5-YEAR PREDICTED SURVIVAL
All Study Patients
Patients Stratified by 5-Year Predicted Survival 
Control Patients Transplant Recipients
Variable (except as noted, % affected) Control Transplant <  50% 50-90% <  50% 50-90%
No. patients 12,826 845 579 2,539 347 471
Deaths 9.3 36.0 55.4 24.1 41.8 36.1
Age, yr, mean ± SD 25.1 ± 9.1 25.1 ± 9.0 25.3 ± 9.1 23.6 ± 9.7 25.7 ± 8.2 24.8 ± 9.6
Acute exacerbations, mean no./yr ± SD 0.90 ± 1.44 2.75 ± 1.74 4.05 ± 1.40 2.15 ± 1.61 4.02 ± 1.22 1.93 ± 1.50
Arthropathy 1.42 1.78 2.9 3.2 2.6 1.3
Burkholderia cepacia 4.26 7.57 19.5 11.9 12.4 4.4
Diabetes 6.55 16.6 25.7 14.4 26.8 9.5
FEV,%, % ± SD 76.0 ± 28.8 28.6 ± 1 1 .8 28.8 ± 9.4 45.1 ± 15.1 24.8 ± 7.3 29.7 ± 10.6
Sex, % male 47.2 47.1 52.8 50.7 53.9 43.3
Pancreatic sufficiency 6.4 2.72 1.9 3.4 1.7 3.0
Staphylococcus aureus 42.3 23.4 20.9 30.8 18.2 25.7
Weight for age z score, ± SD -0.71 ± 1.05 -1 .4 6  ± 1.00 -1 .9 6  ± 0.87 -1 .2 8  ± 0.95 -1 .8 2  ± 0.90 -1 .2 2  ± 0.96
As a group, transplant recipients have lower FEV % and weight-for-age z score, and more acute exacerbations, pancreatic insufficiency, diabetes, and infections 
(except 5. aureus) than control patients. After stratification by S-year predicted survival, significant differences were minimized between control and transplant patients. 
For example, our S-year predicted survival model adjusts for significant differences in prevalence of 8. cepacia infection between low predicted survival control and 
transplant patients.
interaction of age and B. cepacia infection status appeared in 
the final Cox model for post-transplantation survival.
Two variables included in consensus guidelines for patient 
selection for lung transplantation (19, 20), sex and weight, were 
eliminated from the final Cox model. We examined weight-for- 
age z score distribution among control subjects and transplant 
recipients to see if there was a selection bias that might have 
compromised our ability to find a significant influence on post­
transplantation survival. We found no evidence of such a bias 
(Kolmogorov-Smirnov test [18], p = 0.08).
We illustrate two selected features of our post-transplantation 
Cox model with Kaplan-Meier survival curves. The progressive 
improvement in lung transplantation over time is shown by com­
paring survival for patients transplanted 1991-1997 and 1998-2001 
(Figure 1). There were 473 patients who underwent transplanta­
tion during 1991-1997 and 372 patients during 1998-2001.
CF-related arthropathy affected 15 patients who underwent 
lung transplantation. It was not reported in the other 830 patients 
in our transplant group. Arthropathy had the largest hazard ratio 
in our Cox model (Table 3). The arthropathy-affected transplant 
recipients had a much worse post-transplantation survival com­
pared with other transplant recipients (Figure 2). Ten of the 
patients died during the initial 5 years of follow-up; half of the 
deaths occurred during the first 6 months post-procedure.
Impact on Patient Selection for Lung Transplantation
We estimated the survival effect of arthropathy, B. cepacia infec­
tion, and age on transplanted patients compared with control
subjects stratified by 5-year predicted survival. First, we consid­
ered the effect of age on transplant recipients uninfected by B. 
cepacia. Even those children with 5-year predicted survival of 
less than 50% had no survival benefit from lung transplantation 
(Figure 3A). Adults with a less than 50% 5-year predicted sur­
vival had a slight survival disadvantage related to transplanta­
tion, which persisted for a year after the procedure, but the 
survival curves crossed at 1 year and resulted in a net survival 
benefit of lung transplantation for these patients after 5 years 
of follow-up (Figure 3C). As expected (6), both children (Figure 
3B) and adults (Figure 3D) with 5-year predicted survival be­
tween 50 and 90% had a significant decrease in survival related 
to lung transplantation.
Second, we considered the effects of age for transplant recipi­
ents infected with B. cepacia. Children (<18  years) infected with 
B. cepacia had no survival effect related to lung transplantation 
whether they had a 5-year predicted survival of less than 50% 
(Figure 4A) or 50 to 90% (Figure 4B), although it should be 
noted that there were only nine patients and two deaths in 
the latter group. Adults with B. cepacia infection with a 5-year 
predicted survival of less than 50% (Figure 4C) suffered de­
creased survival after transplantation. Adults with B. cepacia 
infection and 5-year predicted survival of 50 to 90% (Figure 4D) 
had no survival benefit. Finally, patients with arthropathy and 
either low or high 5-year predicted survival did poorly with 
transplantation, primarily because of early postoperative deaths 
compared with other transplant recipients (Figure 2), and had no
TABLE 3. MULTIVARIATE COX PROPORTIONAL HAZARDS MODEL OF THE HAZARD 
OF DEATH AFTER LUNG TRANSPLANTATION
Variable Coefficient SE Hazard Ratio
95% Confidence 
Interval p Value
Age -0 .0252 0.0067 0.975 0.96-0.99 <  0.001
Arthropathy 0.802 0.32 2.23 1.19-4.18 0.013
8. cepacia -0 .723 0.62 0.485 0.144-1.636 0.24
Year of Transplant -0 .0618 0.022 0.94 0.90-0.98 0.006
Age X 8. cepacia 0.0587 0.024 1.060 1.01-1.12 0.013
The model includes four variables and a single interaction term. B. cepacia as a single variable does not reach statistical significance 
but is included because of the strong and significant interaction term with age. The model demonstrates that the hazard of death 
after lung transplantation for cystic fibrosis has improved by approximately 6%/year between 1991 and 2001. See text for other 
discussion and Figure 1.
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Figure 1. Survival post-transplan­
tation for patients with CF has im­
proved with time as shown by sur­
vival in two transplantation eras. 
Post-transplantation survival for 
473 patients (21 7 deaths) with 
CF transplantation from 1991 
through 1997 is compared to 
survival for 372 patients (87 
deaths) transplanted from 1998 
through 2001. The hazard ratio 
of death in each year is 94% of 
the hazard in the previous year 
(p = 0.006, from Table 3). Thus, 
for example, the hazard for pa­
tients transplanted in 1996 is
0.73 compared with patients 
transplanted in 1991.
improvement in survival when compared with nontransplanted 
patients with arthropathy (not shown).
DISCUSSION
The intention of lung transplantation is to improve outcomes for 
patients with CF. Clinicians focus on post-transplantation survival 
as the easiest measure of efficacy. However, post-transplantation 
survival must be compared with nontransplanted survival to obtain 
a complete picture of the survival effect of transplantation. Factors 
present pretransplantation that affect post-transplantation sur­
vival may help identify individuals who will have improved post­
transplantation survivorship.
A transplantation selection factor such as age, that predicts 
longer post-transplantation survival is an indication for transplanta­
tion only if it also predicts an increase in survival compared with 
nontransplantation. A factor that predicts decreased survival in a 
transplant recipient relative to other transplant recipients might 
still result in survival benefit when comparing post-transplantation 
survival to nontransplanted survival within a 5-year predicted sur­
vival stratum. In the case of patients with B. cepacia, infection 
decreases survival post-transplantation but also decreases nontrans­
planted survival. Potentially, the negative survival impact of 
B. cepacia infection might be lessened in transplanted patients 
compared with nontransplanted control subjects, resulting in a sur-
Figure 2. Substantial effect of 
arthropathy on post-transplan­
tation survival is shown. Pa­
tients with CF and with arthrop­
athy were rare as reflected in 
the small number of transplant 
recipients with arthropathy (15). 
Survival was compared with 
830 transplant recipients not 
affected by arthropathy. De­
spite small numbers, the effect 
of arthropathy on post-trans­
plantation survival was pro­
found (hazard ratio, 2.23; p = 0.01 3; fromTable 3) and persisted beyond
5 years of follow-up. There were 10 deaths among the 15 transplant 
recipients with arthropathy compared with 320 deaths among the 830 
recipients without arthropathy.
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Figure 3. Age affects survival following lung transplantation for CF. 
Patients infected with B. cepacia are excluded from this analysis. Year 
of transplantation had no correlation with either age at transplantation 
or 5-year predicted survival. Patients with arthropathy are included in 
this analysis but were too few to have any effect on results. (/\) Children 
with a 5-year predicted survival of less than 50% had no survival benefit 
from lung transplantation. Survival for 57 transplant recipients younger 
than 18 years (28 deaths) and 1 39 control subjects (73 deaths) is shown. 
(B) Children with a 5-year predicted survival between 50 and 90% 
had decreased survivorship from lung transplantation. Survival for 127 
transplant recipients (61 deaths) and 720 control patients (181 deaths) 
is shown. (C) Adults with a 5-year predicted survival of less than 50% 
had a survival advantage from transplantation. Survival for 362 control 
patients (198 deaths) and 258 transplant recipients (with 85 deaths) 
is shown. (D) Adults with a 5-year predicted survival between 50 and 
90% did poorly with lung transplantation. Survival for 330 transplant 
recipients (96 deaths) and 1,532 control patients (354 deaths) is show'n.
We examined 24 clinical variables, including 5-year predicted 
survival (Table 1), to discover whether any had a significant 
effect on survival after lung transplantation. The 5-year predicted 
survival itself and variables incorporated into the 5-year pre­
dicted survival prediction other than age or B. cepacia infection 
had no effect on post-transplantation survival (Table 3) (6, 7).
Body weight is used by 79% of lung transplantation centers 
in the United States to select patients for the procedure (21). 
Our analysis found that there was no effect of body weight 
or of other nutritional factors on post-transplantation survival 
(Table 1). Patient selection procedures that use body weight 
already in place at transplant centers might have biased our 
analysis, but we found that there was no difference in weight- 
for-age z score distribution between transplanted and nontrans­
planted patients with 5-year predicted survival less than 50%. 
This suggests that body weight may not be rigorously used as a 
selection criterion for transplantation, but our analysis suggests 
that there may be no need for this criterion.
A sex-based selection preference for lung transplantation has 
been suggested (19, 20) because of the decreased survival of 
females with CF compared with males (5, 22). Our method of 
patient selection for transplantation (6) incorporates sex into 
the calculations of weight-for-age z score, FEV,%, and 5-year 
predicted survival. Our new finding that sex caused no direct
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Figure 4. The survival effect of B. cepacia infection for lung transplant 
recipients by age and predicted survival status is shown. For children 
infected with B. cepacia, survival is unchanged by lung transplantation 
whether 5-year predicted survival is (A) less than 50% or (B) between 
50 and 90%. A shows survival of 22 control patients younger than 18 
years (1 3 deaths) and 12 transplant recipients younger than 18 years 
(6 deaths). B shows survival of 127 control patients younger than 18 
years (42 deaths) and 9 transplant patients younger than 18 years (2 
deaths). (C) Adults with 8. cepacia infection suffered a survival decrease 
with lung transplantation even though nontransplanted 5-year pre­
dicted survival was already poor. Survival of 91 control patients (55 
deaths) and 31 transplant recipients (19 deaths) is shown. (D) Adults 
with B. cepacia infection with a pretransplantation 5-year predicted 
survival between 50 and 90% had no survival benefit with lung trans­
plantation. Survival of 1 74 control patients (42 deaths) and 12 transplant 
recipients (4 deaths) is shown.
post-transplantation survival effect demonstrates that it need not 
be Separately considered as a criterion for lung transplantation.
Somewhat unexpectedly, we found a significant reduction in 
hazard of death post-transplantation for patients who underwent 
transplantation later during the study period (Table 3). Careful 
inspection of the Kaplan-Merer survival plot comparing the 1998­
2001 cohort of transplanted patients with the 1991-1997 cohort 
revealed that the gain appears to be because of improved survival 
during the first 6 months post-transplantation (Figure 1).
Three patient-specific factors available before transplantation 
appear to significantly alter post-transplantation survival: CF- 
related arthropathy, B. cepacia infection, and younger age. CF- 
related arthropathy is a variable, ill-defined condition with no 
clear etiology, diagnostic algorithm, or uniformly effective treat­
ment (23). Patients frequently have joint pain but lack history 
of injury, clear association with other characteristic findings of 
CF, evidence of articular erosions or positive markers, such as 
rheumatoid factor, or autoimmune-related arthritis. In our prior 
study of survival in CF (5), arthropathy had no impact on sur­
vival. However, in recipients of lung transplantation, arthropathy 
appeared to have a profound independent negative effect on 
post-transplantation survival, especially within 2 months of trans­
plantation (Figure 2).
Our results, although significant (Table 3), depend on the 
outcomes of only 15 transplanted patients with CF-related ar­
thropathy compared with 830 transplant recipients without ar­
thropathy. Arthropathy is likely to be greatly underreported. Up 
to one-third of patients with CF have some type of arthropathy or 
arthritis (23). However, only 1.5% of patients in our control 
group were recorded to have arthropathy. These results suggest 
that clinicians should take arthropathy into account when consid­
ering lung transplantation. But arthropathy should not be consid­
ered a contraindication until there is a better disease definition, 
better reporting, more information about pathophysiology, and 
more long-term post-transplantation survivorship data.
The hazard of death decreased with increasing age at trans­
plantation. One quarter of transplanted patients were younger 
than 18 years. Comparison of survival between young trans­
planted and control patients without B. cepacia infection showed 
that younger patients did not derive survival benefit from lung 
transplantation, even with low 5-year predicted survival (Figure 
3A). The survival benefit of lung transplantation among patients 
with low 5-year predicted survival seen in our earlier study came 
entirely from adult transplant recipients (Figure 3 0  (6).
Using CFFPR and UNOS data, we can only speculate about 
possible causes for the increased hazard of death after trans­
plantation in pediatric patients with CF. We found a nonsignifi­
cantly higher hazard of death among patients aged 14 to 17 years 
compared with even younger transplant recipients (data not 
shown). Rapid growth, physical and emotional maturation, and 
large social changes occur in this age range. These factors may 
contribute to poorer transplantation outcomes. For example, young 
transplant recipients likely benefit from constant parental remind­
ers to take transplantation medications but, as a consequence, may 
not internalize understanding of the need for treatment. This may 
predispose to decreased compliance with post-transplantation man­
agement in adolescence, a period when conflicts between children 
and parents often arise in the CF as well as in the general popula­
tion.
Our results may suggest a rigid cutoff age of 18 for lung 
transplantation. Comparison between pediatric recipients and 
the next quartile of transplant recipients, aged 18 to 24 years, 
showed a sharp and significant improvement in survival benefit 
when transplanted survival was compared with nontransplanted 
survival (data not shown). Young patients, their families, and 
physicians contemplating lung transplantation must consider 
that increased survival is relatively unlikely, especially if the 
patient is younger than 18 years with a 5-year predicted survival 
greater than 50%.
Immediate or rapid transplantation in the pediatric age group 
should be considered only if there are compelling reasons for 
transplantation other than improved survival. Those pediatric 
patients weighing the risks and benefits of transplantation during 
adolescence may wish to consider maximizing other therapies 
for CF and delaying transplantation until after reaching age 18. 
Besides moving into a more favorable transplant group (Figure 
3), the passage of time may allow significant improvements in 
the procedure itself (Figure 1).
Our Cox model confirms past reports of decreased post­
transplantation survival for patients infected with B. cepacia 
compared with post-transplantation survival of patients without 
B. cepacia infection (8,10,11). Our sample of B. cepacia-mfect&d 
transplant recipients is larger than any prior report, allowing 
our model to detect a strong interaction between B. cepacia 
infection and age (Table 3) and allowing us to analyze survival 
effect stratified by age and 5-year predicted survival.
Because of the interaction, pediatric transplant recipients with 
B. cepacia infection did not suffer decreased post-transplantation 
survival relative to uninfected pediatric recipients of transplanta­
tion. In contrast, adult transplant recipients had a marked decrease 
in survival related to B. cepacia infection. Comparison of post­
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transplantation survival to nontransplanted survival in patients 
stratified by 5-year predicted survival showed no survival benefit 
of lung transplantation regardless of 5-year predicted survival for 
young patients (Figures 4A and 4B) and adult patients with high 
predicted survival (Figure 4D), and actual harm for adult patients 
with low predicted survival (Figure 4C).
Our study has some limitations. It is retrospective, and selec­
tion of patients for lung transplantation may have changed during 
the period of study. We have limited ability to detect biases in 
selection for transplantation, and the use of our 5-year survival 
prediction model to stratify patients for analysis may not have 
fully controlled for subtle biases. Using the 5-year predicted 
survival excluded a few patients who were too ill to perform 
pulmonary function testing. However, we were able to include 
84% of transplanted patients and 87% of control patients older 
than 5.5 years. Although our results apply only to patients with 
complete data for calculating a 5-year predicted survival, the 
high percentage of inclusion suggests broad generalizability.
We could not consider other variables, not tracked by the 
CFFPR, that may have a significant impact on survival in CF and 
lung transplantation. For example, our model did not consider 
hypercapnia, which may independently identify gravely ill pa­
tients (24). Patients so desperately ill as to require mechanical 
ventilation have been shown to have survival benefit from lung 
transplantation if suitable organs could be found in time (25, 
26). In practice, however, the challenge of finding suitable organs 
in time for such patients is often insurmountable.
Furthermore, this retrospective study cannot address all ques­
tions about the survival effect of B. cepacia on lung transplantation. 
We cannot account for the possibility of improving treatments for 
B. cepacia infection with and without transplantation that might 
have improved outcomes (8). Because there is insufficient informa­
tion in the CFFPR, we were unable to distinguish differing survival 
patterns among patients infected with different genomovars of
B. cepacia. Although patients with B. cepacia infection did poorly 
with transplantation and did not have a survival benefit from the 
procedure, we cannot tell if there might be a subset of patients with
B. cepacia who would do better. Although collection of additional 
genomovar information is desirable, we are uncertain if it will be 
helpful. New information suggests that infections even by a single 
genomovar of B. cepacia may have greatly differing severity 
depending on the patient or geographic region (27).
Finally, our study, by the nature of the data, cannot give 
direct guidance to those patients seeking improved quality of life 
even at the expense of shortened survival. As we have previously 
conjectured, poor quality of life may correlate with low 5-year 
predicted survival (6, 7, 28). Thus, the greatest improvement in 
quality of life may accompany the greatest survival benefit of 
lung transplantation. Data do not exist that would allow a test 
of this hypothesis. We are hopeful, however, that new methods 
for measuring quality of life will facilitate such a test (29).
Clinicians should seek lung transplantation for patients only 
if there is an increase in survival relative to nontransplanted 
survival. They should avoid transplantation for patients who 
will suffer harm, even if post-transplantation survival appears 
favorable compared with other transplant recipients. Focusing 
only on post-transplantation survival without considering sur­
vival benefit relative to nontransplantation risks maximizing 
graft survival at the expense of decreased patient survival. For 
patients likely to have survival benefit, the amount of benefit 
and the length of post-transplantation survival may help decide 
how best to allocate scarce donor organs.
Our validated 5-year predictive model made it possible to 
stratify transplanted and control patients by survivorship. Our 
study confirms that patients with 5-year predicted survival greater 
than 50% should not be transplanted in order to avoid reducing
survival. Moreover, we found no survival benefit of lung trans­
plantation for children or for patients of any age infected with B. 
cepacia. For patients with 5-year predicted survival of less than 
50%, we recommend that patients and physicians temper their 
expectations of survival benefit from lung transplantation when 
patients are young or infected with B. cepacia. CF-related arthrop­
athy should be a concern for possible transplant recipients but 
not a contraindication. Because there is an ongoing shortage 
of suitable organs for transplantation, those patients seeking 
improved quality of life despite a likely reduction in survival 
should be deferred in favor of patients likely to have survival 
benefit from transplantation in addition to any possible improve­
ment in quality of life because of better lung function.
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